Literature DB >> 22915797

Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.

Natalia A Ilyushina1, Mine R Ikizler, Yoshihiro Kawaoka, Larisa G Rudenko, John J Treanor, Kanta Subbarao, Peter F Wright.   

Abstract

Although clinical trials with human subjects are essential for determination of safety, infectivity, and immunogenicity, it is desirable to know in advance the infectiousness of potential candidate live attenuated influenza vaccine strains for human use. We compared the replication kinetics of wild-type and live attenuated influenza viruses, including H1N1, H3N2, H9N2, and B strains, in Madin-Darby canine kidney (MDCK) cells, primary epithelial cells derived from human adenoids, and human bronchial epithelium (NHBE cells). Our data showed that despite the fact that all tissue culture models lack a functional adaptive immune system, differentiated cultures of human epithelium exhibited the greatest restriction for all H1N1, H3N2, and B vaccine viruses studied among three cell types tested and the best correlation with their levels of attenuation seen in clinical trials with humans. In contrast, the data obtained with MDCK cells were the least predictive of restricted viral replication of live attenuated vaccine viruses in humans. We were able to detect a statistically significant difference between the replication abilities of the U.S. (A/Ann Arbor/6/60) and Russian (A/Leningrad/134/17/57) cold-adapted vaccine donor strains in NHBE cultures. Since live attenuated pandemic influenza vaccines may potentially express a hemagglutinin and neuraminidase from a non-human influenza virus, we assessed which of the three cell cultures could be used to optimally evaluate the infectivity and cellular tropism of viruses derived from different hosts. Among the three cell types tested, NHBE cultures most adequately reflected the infectivity and cellular tropism of influenza virus strains with different receptor specificities. NHBE cultures could be considered for use as a screening step for evaluating the restricted replication of influenza vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915797      PMCID: PMC3486302          DOI: 10.1128/JVI.01477-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice.

Authors:  M D Wareing; J M Watson; M J Brooks; G A Tannock
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

Review 2.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; W Abdullah Brooks; Mark Katz; Anna Roca; James A Berkley; Shabir A Madhi; James Mark Simmerman; Aubree Gordon; Masatoki Sato; Stephen Howie; Anand Krishnan; Maurice Ope; Kim A Lindblade; Phyllis Carosone-Link; Marilla Lucero; Walter Ochieng; Laurie Kamimoto; Erica Dueger; Niranjan Bhat; Sirenda Vong; Evropi Theodoratou; Malinee Chittaganpitch; Osaretin Chimah; Angel Balmaseda; Philippe Buchy; Eva Harris; Valerie Evans; Masahiko Katayose; Bharti Gaur; Cristina O'Callaghan-Gordo; Doli Goswami; Wences Arvelo; Marietjie Venter; Thomas Briese; Rafal Tokarz; Marc-Alain Widdowson; Anthony W Mounts; Robert F Breiman; Daniel R Feikin; Keith P Klugman; Sonja J Olsen; Bradford D Gessner; Peter F Wright; Igor Rudan; Shobha Broor; Eric A F Simões; Harry Campbell
Journal:  Lancet       Date:  2011-11-10       Impact factor: 79.321

Review 3.  Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.

Authors:  Brian R Murphy; Kathleen Coelingh
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

4.  Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers.

Authors:  M L Clements; R F Betts; H F Maassab; B R Murphy
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

5.  Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides.

Authors:  N V Bovin; T V Zemlyanukhina; N E Byramova; O E Galanina; A E Zemlyakov; A E Ivanov; V P Zubov; L V Mochalova
Journal:  Glycoconj J       Date:  1993-04       Impact factor: 2.916

6.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

7.  Laboratory characterization of a swine influenza virus isolated from a fatal case of human influenza.

Authors:  P A Rota; E P Rocha; M W Harmon; V S Hinshaw; M G Sheerar; Y Kawaoka; N J Cox; T F Smith
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

8.  Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection.

Authors:  M L Clements; R F Betts; B R Murphy
Journal:  Lancet       Date:  1984-03-31       Impact factor: 79.321

9.  Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants.

Authors:  Y Z Ghendon; F I Polezhaev; K V Lisovskaya; T E Medvedeva; G I Alexandrova; A I Klimov
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

10.  A solid-phase enzyme-linked assay for influenza virus receptor-binding activity.

Authors:  A S Gambaryan; M N Matrosovich
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014

View more
  32 in total

1.  Pandemic Seasonal H1N1 Reassortants Recovered from Patient Material Display a Phenotype Similar to That of the Seasonal Parent.

Authors:  Stephanie Sonnberg; Mariette F Ducatez; Jennifer DeBeauchamp; Jeri-Carol Crumpton; Adam Rubrum; Bridgett Sharp; Richard J Hall; Matthew Peacey; Sue Huang; Richard J Webby
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

2.  Validation of normal human bronchial epithelial cells as a model for influenza A infections in human distal trachea.

Authors:  A Sally Davis; Daniel S Chertow; Jenna E Moyer; Jon Suzich; Aline Sandouk; David W Dorward; Carolea Logun; James H Shelhamer; Jeffery K Taubenberger
Journal:  J Histochem Cytochem       Date:  2015-01-20       Impact factor: 2.479

3.  Role of Substitutions in the Hemagglutinin in the Emergence of the 1968 Pandemic Influenza Virus.

Authors:  Sjouke Van Poucke; Jennifer Doedt; Jan Baumann; Yu Qiu; Tatyana Matrosovich; Hans-Dieter Klenk; Kristien Van Reeth; Mikhail Matrosovich
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

4.  Improving risk assessment of the emergence of novel influenza A viruses by incorporating environmental surveillance.

Authors:  Kim M Pepin; Matthew W Hopken; Susan A Shriner; Erica Spackman; Zaid Abdo; Colin Parrish; Steven Riley; James O Lloyd-Smith; Antoinette J Piaggio
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-08-12       Impact factor: 6.237

5.  H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.

Authors:  Rita Czakó; Leatrice Vogel; Troy Sutton; Yumiko Matsuoka; Florian Krammer; Zhongying Chen; Hong Jin; Kanta Subbarao
Journal:  Vaccine       Date:  2018-03-01       Impact factor: 3.641

6.  Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures.

Authors:  William A Fischer; Kelly D Chason; Missy Brighton; Ilona Jaspers
Journal:  Vaccine       Date:  2014-01-30       Impact factor: 3.641

7.  The M2 protein of live, attenuated influenza vaccine encodes a mutation that reduces replication in human nasal epithelial cells.

Authors:  Nicholas Wohlgemuth; Yang Ye; Katherine J Fenstermacher; Hsuan Liu; Andrew P Lane; Andrew Pekosz
Journal:  Vaccine       Date:  2017-10-25       Impact factor: 3.641

8.  Chronic exposure to arsenite enhances influenza virus infection in cultured cells.

Authors:  Eva A Amouzougan; Ricardo Lira; Walter T Klimecki
Journal:  J Appl Toxicol       Date:  2020-01-20       Impact factor: 3.446

9.  Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses.

Authors:  Jun-Gyu Park; Ginés Ávila-Pérez; Aitor Nogales; Pilar Blanco-Lobo; Juan C de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

10.  Evaluation of the innate immune responses to influenza and live-attenuated influenza vaccine infection in primary differentiated human nasal epithelial cells.

Authors:  Adriana Forero; Katherine Fenstermacher; Nicholas Wohlgemuth; Andrew Nishida; Victoria Carter; Elise A Smith; Xinxia Peng; Melissa Hayes; Doreen Francis; John Treanor; Juliet Morrison; Sabra L Klein; Andrew Lane; Michael G Katze; Andrew Pekosz
Journal:  Vaccine       Date:  2017-09-28       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.